efanesoctacog alpha

Phase 3Small molecule

efanesoctacog alpha is one of 3 small molecule programs targeting Hemophilia A With Inhibitor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemophilia a With InhibitorNot yet recruiting

Hemophilia a With InhibitorPhase 3

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Hemophilia a With Inhibitor

#DrugCompanyPhaseTrials

Hemlibra

Roche

Approved

1 2

efanesoctacog alpha

VVersiti Blood Health

Phase 3

1 3

Elranatamab

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

ApprovedNot yet recruiting

Hemophilia a With Inhibitor

NCT07158606

Clinical

Trials by Indication[1]

Hemophilia A With Inhibitor1 trial

Understanding Treatment Outcomes and Immunologic Mechanisms in ALtuviiio Immune Tolerance Induction

Not yet recruiting·VVersiti Blood Health·Approved·NCT07158606·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for efanesoctacog alpha. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — efanesoctacog alpha compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for efanesoctacog alpha. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Versiti Blood Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVersiti Blood Health

efanesoctacog alpha

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Trials by Indication[1]

Hemophilia A With Inhibitor1 trial

References

Drug Info

Quick Facts

Related News